Jason Rhodes Biography and Net Worth

Director of Dyne Therapeutics

Jason is a partner with Atlas Venture, where he focuses on creating and building novel therapeutics companies. He is a founder and the chairman of Dyne, Generation Bio (NASDAQ: GBIO), Rectify Pharmaceuticals, and Disarm Therapeutics (acquired by Lilly). He was also previously on the board of Replimune (NASDAQ: REPL).

Jason received his B.A. from Yale University and his M.B.A. from the Wharton School of the University of Pennsylvania.

What is Jason P. Rhodes' net worth?: The estimated net worth of Jason P. Rhodes is at least $10.41 million as of August 14th, 2026. Mr. Rhodes owns 428,946 shares of Dyne Therapeutics stock worth more than $10,414,809 as of September 5th. This net worth approximation does not reflect any other assets that Mr. Rhodes may own. Learn More about Jason P. Rhodes' net worth.
How do I contact Jason P. Rhodes?: The corporate mailing address for Mr. Rhodes and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at [email protected]. Learn More on Jason P. Rhodes' contact information.
Has Jason P. Rhodes been buying or selling shares of Dyne Therapeutics?: Within the last three months, Jason P. Rhodes has sold $83,042,691.86 of Dyne Therapeutics stock. Most recently, Jason P. Rhodes sold 2,160,516 shares of the business's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $25.00, for a transaction totalling $54,012,900.00. Following the completion of the sale, the director now directly owns 428,946 shares of the company's stock, valued at $10,723,650. Learn More on Jason P. Rhodes' trading history.
Who are Dyne Therapeutics' active insiders?: Dyne Therapeutics' insider roster includes Oxana Beskrovnaya (Chief Scientific Officer), Joshua Brumm (CEO), John Cox (President & CEO), Wildon Farwell (Insider), Johanna Friedl-Naderer (Chief Commercial Officer), Susanna High (COO), Carlo Incerti (Director), Douglas Kerr (Insider), Dirk Kersten (Director), Erick Lucera (CFO), Brian Posner (Director), Jason Rhodes (Director), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.
Are insiders buying or selling shares of Dyne Therapeutics?: During the last year, Dyne Therapeutics insiders bought shares 5 times. They purchased a total of 12,000 shares worth more than $201,980.00. During the last year, insiders at the sold shares 25 times. They sold a total of 5,701,298 shares worth more than $129,300,000.63. The most recent insider tranaction occured on August, 14th when Director Jason P. Rhodes sold 2,160,516 shares worth more than $54,012,900.00. Insiders at Dyne Therapeutics own 9.5% of the company. Learn More about insider trades at Dyne Therapeutics.
Information on this page was last updated on 8/14/2026.

Jason P. Rhodes Insider Trading History at Dyne Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/14/2026	Sell	2,160,516	$25.00	$54,012,900.00	428,946
8/13/2026	Sell	426,412	$26.20	$11,171,994.40	751,411
7/7/2026	Sell	297,211	$23.26	$6,913,127.86	2,962
7/6/2026	Sell	480,240	$22.79	$10,944,669.60	875,912
6/29/2026	Sell	195,427	$21.14	$4,131,326.78	975,931
6/26/2026	Sell	309,268	$21.28	$6,581,223.04	1,016,633
6/25/2026	Sell	24,100	$21.10	$508,510.00	1,081,044
6/24/2026	Sell	95,900	$21.02	$2,015,818.00	1,086,063
6/23/2026	Sell	147,760	$21.13	$3,122,168.80	1,106,036
5/6/2026	Sell	83,219	$18.18	$1,512,921.42	7,962
5/5/2026	Sell	11,600	$18.03	$209,148.00	8,390
5/4/2026	Sell	11,904	$18.00	$214,272.00	8,450
4/28/2026	Sell	227,337	$18.38	$4,178,454.06	8,511
4/27/2026	Sell	173,493	$18.15	$3,148,897.95	9,682
4/24/2026	Sell	137,948	$18.48	$2,549,279.04	10,576
4/23/2026	Sell	73,108	$19.19	$1,402,942.52	11,286
4/22/2026	Sell	287,956	$19.68	$5,666,974.08	11,663
4/21/2026	Sell	274,297	$19.52	$5,354,277.44	13,148
4/20/2026	Sell	272,049	$20.06	$5,457,302.94	14,561
11/14/2024	Sell	782	$33.10	$25,884.20	15,962
2/28/2024	Sell	190,920	$24.84	$4,742,452.80	864,487
2/26/2024	Sell	248,219	$23.72	$5,887,754.68	903,527
2/22/2024	Sell	119,360	$22.66	$2,704,697.60	6,512,104
2/20/2024	Sell	169,539	$22.72	$3,851,926.08	6,815,965
2/15/2024	Sell	177,906	$23.89	$4,250,174.34	7,148,211
12/12/2022	Buy	934,581	$10.70	$10,000,016.70	934,581

Jason P. Rhodes Buying and Selling Activity at Dyne Therapeutics

Dyne Therapeutics Company Overview

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $24.28

$24.14

$24.70

50 Day Range

MA: $24.80

$21.28

$26.78

2 Week Range

Now: $24.28

$11.92

$27.31

Volume

1,588,043 shs

Average Volume

1,710,672 shs

Market Capitalization

$4.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08